Acting simultaneously in the synthetic drugs division…employed at Boehringer Ingelheim and others,
Choi Young-gi, Deputy Director of Central Research Institute, Yuhan Corporation (acting in the synthetic drugs division and executive).(Provided by Yuhan Corporation)/News1 ⓒ News1,
,
, “(Seoul=news1) By Hwang Jin-jung – Yuhan Corporation (000100) announced on the 3rd that they have recruited Choi Young-gi, who has been appointed as the Deputy Director of the Central Research Institute and simultaneously as the head of the synthetic drugs division as of the 1st of this month.”,
,
, “Choi Young-gi, who completed his master’s degree in pharmacy at Seoul National University and obtained a doctorate in chemistry from Oregon State University. In 2005, he gained experience in low molecular weight drug discovery at Boehringer Ingelheim. He was in charge of chemical technology activation work at Forma Therapeutics. He also worked as an executive in charge of discovery research at the Ireland-based bio-pharmaceutical company Alkermes.”,
,
, ‘A Yuhan Corporation official stated, “With the addition of Choi Young-gi, who has nearly 20 years of experience in various global pharmaceutical companies, Yuhan Corporation will inject vitality into various research and development (R&D) activities.”‘,
,
, “Meanwhile, Yuhan Corporation, on the verge of its 100th anniversary in 2026, has developed ‘Lexaza’ (ingredient name Lazertinib), a non-small cell lung cancer treatment that is expected to be approved by the U.S. Food and Drug Administration (FDA) as the 31st new drug in Korea and a future global blockbuster drug. They are making strides as a global leading company in new drug development by operating over 30 new drugs in pipelines, including numerous immune-oncology drugs.”